Samsung Bioepis Clears Up Second EU Bevacizumab Application
Market Entry Also Confirmed For Aybintio Biosimilar
Samsung Bioepis last week received a second positive opinion recommending granting a pan-European marketing authorization for a biosimilar bevacizumab product. The Korean firm spoke to Generics Bulletin detailing the rationale.
You may also be interested in...
Samsung Bioepis reiterated that the US pharma market is “the most fragmented and the most complicated market in the world” as it discussed its biosimilar fortunes in Europe.
Merck & Co has disclosed more precise details around plans to spin off its more mature products, including biosimilars, into a new publicly traded company.
Samsung Bioepis is lining up two biosimilar bevacizumab products in the EU, after the EMA’s CHMP recommended the company’s Onbevzi product months after approval for Aybintio.